doi:https://doi.org/

References:

Levine G.N., Bates E.R., Bittl J.A., et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016;68:1082—1115.
Valgimigli M., Bueno H., Byrne R.A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213—260.
Motovska Z., Bhatt D.L. 12 months of DAPT after acute coronary syndrome still beats 6 months. Lancet. 2018 Mar 9. pii: S0140-6736(18)30612-3. doi:10.1016/S0140-6736(18)30612-3. [Epub ahead of print].
Mehran R., Baber U., Steg P.G., et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382:1714—1722.
Bhatt D.L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007;357:2078—2081.
Mak K.H., Bhatt D.L., Shao M., et al. Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. Am Heart J 2009;157:658—665.
Levine G.N., Jeong Y.H., Goto S., et al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014;11:597—606.
Varenhorst C., Hasvold P., Johansson S., et al. Culprit and nonculprit recurrent ischemic events in patients with myocardial infarction: data from SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies). J Am Heart Assoc 2018;7:e007174.
Giustino G., Mehran R., Dangas G.D., et al. Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI. J Am Coll Cardiol 2017;70:1846—1857.
Cuisset T., Deharo P., Quilici J., et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017;38:3070—3078.
Sibbing D., Aradi D., Jacobshagen C., et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017;390:1747—1757.
Motovska Z., Hlinomaz O., Kala P., et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol 2018;71:371—381.
Costa F., van Klaveren D., James S., et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025—1034.
Connolly S.J., Eikelboom J.W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:205—218.